BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi...
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series...
T&L Biotechnology Secures RMB 100 Million in Series A Financing
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB...
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing...
LBX Pharmacy Partners with Gilead Sciences to Enhance Disease Management in China
China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD)....
Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has...
WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech
German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication...
NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...
SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...
Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns
US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...
BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia
US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...
Gracell Secures Non-Exclusive License for Cell Therapies from Seagen
China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and...
Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development
Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised...
Hainan Poly Pharm’s Generic Gadovist Receives FDA Approval for MRI Use
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received marketing...
Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study
China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...
Hengrui Pharmaceuticals’ Dexmedetomidine Nasal Spray Approved by NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing...